Pancras CW Hogendoorn
Pancras CW Hogendoorn
Professor of Pathology, Leiden University Medical Center
Verified email at lumc.nl
Title
Cited by
Cited by
Year
World Health Organization classification of tumours
DM Christopher
Pathology & Genetic: Tumours of Soft Tissue and Bone, 2000
4949*2000
WHO classification of tumours of soft tissue and bone
JA Bridge, P Hogendoorn, C DM, JA Bridge, P CW, CDM Fletcher
International Agency for Research on Cancer, 2013
35002013
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, ...
The Lancet 364 (9440), 1127-1134, 2004
18732004
Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
JY Blay, S Bonvalot, P Casali, H Choi, M Debiec-Richter, AP Dei Tos, ...
Annals of Oncology 16 (4), 566-578, 2005
9452005
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
MF Amary, K Bacsi, F Maggiani, S Damato, D Halai, F Berisha, R Pollock, ...
The Journal of pathology 224 (3), 334-343, 2011
7672011
Sarcoma derived from cultured mesenchymal stem cells
J Tolar, AJ Nauta, MJ Osborn, A Panoskaltsis Mortari, RT McElmurry, ...
Stem cells 25 (2), 371-379, 2007
7552007
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ...
The lancet oncology 15 (4), 415-423, 2014
6202014
The clinical approach towards chondrosarcoma
H Gelderblom, PCW Hogendoorn, SD Dijkstra, CS Van Rijswijk, AD Krol, ...
The oncologist 13 (3), 320-329, 2008
5982008
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
I Ray-Coquard, C Cropet, M Van Glabbeke, C Sebban, A Le Cesne, ...
Cancer research 69 (13), 5383-5391, 2009
5122009
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are …
J Verweij, A van Oosterom, JY Blay, I Judson, S Rodenhuis, ...
European Journal of Cancer 39 (14), 2006-2011, 2003
4702003
Langerhans cell histiocytosis
RM Egeler, GJ D'Angio
The Journal of pediatrics 127 (1), 1-11, 1995
4031995
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
JK Anninga, H Gelderblom, M Fiocco, JR Kroep, AHM Taminiau, ...
European journal of cancer 47 (16), 2431-2445, 2011
3872011
Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study
WG Goettsch, SD Bos, N Breekveldt-Postma, M Casparie, RMC Herings, ...
European journal of cancer 41 (18), 2868-2872, 2005
3832005
The histopathological differential diagnosis of gastrointestinal stromal tumours
JFG van Roggen, MLF Van Velthuysen, PCW Hogendoorn
Journal of clinical pathology 54 (2), 96-102, 2001
3702001
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma …
IJ Lewis, MA Nooij, J Whelan, MR Sydes, R Grimer, PCW Hogendoorn, ...
Journal of the National Cancer Institute 99 (2), 112-128, 2007
3612007
Multiple osteochondromas
JVMG Bovée
Orphanet journal of rare diseases 3 (1), 1-7, 2008
3602008
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
PJ Woll, P Reichardt, A Le Cesne, S Bonvalot, A Azzarelli, HJ Hoekstra, ...
The lancet oncology 13 (10), 1045-1054, 2012
3432012
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and …
M Van Glabbeke, J Verweij, PG Casali, A Le Cesne, P Hohenberger, ...
Journal of Clinical Oncology 23 (24), 5795-5804, 2005
3252005
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents
EP Buddingh, ML Kuijjer, RAJ Duim, H Bürger, K Agelopoulos, ...
Clinical Cancer Research 17 (8), 2110-2119, 2011
2772011
Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2
AB Mohseny, K Szuhai, S Romeo, EP Buddingh, I Briaire‐de Bruijn, ...
The Journal of Pathology: A Journal of the Pathological Society of Great …, 2009
2772009
The system can't perform the operation now. Try again later.
Articles 1–20